H.I.G. Capital News
Tranzyme Pharma Appoints Financial and Pharmaceutical Leader Anne M. VanLent to its Board of Directors
RESEARCH TRIANGLE PARK, N.C. - March 4, 2011 - Tranzyme Pharma today announced the appointment of Anne M. VanLent to its Board of Directors and to serve on and Chair the Company’s Audit Committee.
Ms. VanLent is currently President of AMV Advisors, a company she founded in 2008 to provide corporate strategy and financial consulting to emerging growth life sciences companies. In addition, Ms. VanLent had been Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly-traded pharmaceutical company that develops and markets prescription dermatology products. She was previously Executive Vice President, Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm, and she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. Ms. VanLent also currently serves as a director of and chair of the audit committee of Integra Life Sciences Holding Corporation, a NASDAQ-listed company. She also served as a director of Penwest Pharmaceuticals through its sale to Endo Pharmaceuticals, Inc. in the fall of 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.
“Anne brings an invaluable depth of financial experience and, coupled with her pharmaceutical industry knowledge, will strengthen both our Board and Company,” said Vipin K. Garg, PhD, Tranzyme’s President and CEO.
About Tranzyme Pharma
Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. All of Tranzyme's product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH™, which enables the construction of synthetic libraries of dru-lgike, macrocyclic compounds in a predictable and efficient manner.